Psychosis in Parkinson's and Alzheimer's Disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working, DelveInsight | Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals

Psychosis in Parkinson's and Alzheimer's Disease emerging therapies such as NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others are expected to boost the Psychosis in Parkinson's and Alzheimer's Disease Market in the upcoming years.

DelveInsight has launched a new report on "Psychosis in Parkinson's and Alzheimer's Disease - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Psychosis in Parkinson's and Alzheimer's Disease, historical and forecasted epidemiology as well as the Psychosis in Parkinson's and Alzheimer's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent advancements in the Psychosis in Parkinson's and Alzheimer's Disease Market:
In May 2023, the FDA approved Rexulti (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer's disease. This approval marked the first FDA-sanctioned treatment for such agitation, addressing symptoms like restlessness and aggression that are common in Alzheimer's patients. Clinical trials demonstrated that patients receiving 2 mg or 3 mg of Rexulti showed significant improvements in agitation symptoms compared to those on placebo. Common side effects included headache, dizziness, urinary tract infections, and sleep disturbances.

Some of the key facts of the Psychosis in Parkinson's and Alzheimer's Disease Market Report:

According to DelveInsight's analysis, the psychosis market in Parkinson's disease and Alzheimer's disease across the seven major markets (7MM) was valued at approximately USD 1.29 billion in 2023 and is expected to grow throughout the forecast period from 2024 to 2034.
In 2023, the total number of diagnosed prevalent cases of Parkinson's disease across the seven major markets (7MM) was estimated at 2.6 million. The United States accounted for approximately 45% of these cases, while the EU4 (France, Germany, Italy, and Spain) and the UK collectively made up another 45%. Meanwhile, Japan contributed to 10% of the total diagnosed cases. The prevalence of Parkinson's disease is projected to rise by 2034.
In 2023, an estimated 6.9 million diagnosed prevalent cases of psychosis in Parkinson's disease and Alzheimer's disease were reported in the 7MM. Among these cases, the United States accounted for 34%, while Japan represented nearly 31%, and Germany contributed approximately 11%.
The market for psychosis in Parkinson's and Alzheimer's disease is expected to expand steadily, driven by the introduction of innovative therapies. Key emerging treatments include KarXT (xanomeline-trospium) by Karuna Therapeutics, Ulotaront (SEP-363856) by Sunovion Pharmaceuticals, and ITI-1284 by Intra-Cellular Therapies.
As the aging population continues to grow, the prevalence of Parkinson's disease and Alzheimer's disease is expected to increase, leading to a rising demand for effective psychosis treatments. Greater awareness of psychosis as a significant symptom of these neurodegenerative diseases may contribute to earlier diagnoses and improved treatment options, further driving market expansion.
Despite advancements, significant unmet needs remain in the management of psychosis in Parkinson's and Alzheimer's disease. The absence of curative therapies and reliable biomarkers presents a major challenge. Current screening tools are often complex, making early diagnosis and intervention difficult. While NUPLAZID (pimavanserin) is approved for treating psychosis in Parkinson's disease, there is no equivalent FDA-approved treatment for psychosis in Alzheimer's disease, highlighting a crucial gap in care.
Additionally, psychosis symptoms are frequently underreported or misattributed to other conditions, leading to inaccuracies in epidemiological data and delays in treatment. Addressing these challenges through novel therapies and improved diagnostic approaches will be essential for enhancing patient outcomes and driving further growth in the psychosis treatment market for Parkinson's and Alzheimer's disease.
Key Psychosis in Parkinson's and Alzheimer's Disease companies such as Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others are evaluating new drugs for Psychosis in Parkinson's and Alzheimer's Disease to improve the treatment landscape.
Promising Psychosis in Parkinson's and Alzheimer's Disease pipeline therapies in various stages of development include NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.
Key benefits of the Psychosis in Parkinson's and Alzheimer's Disease market report:
Psychosis in Parkinson's and Alzheimer's Disease market report covers a descriptive overview and comprehensive insight of the Psychosis in Parkinson's and Alzheimer's Disease Epidemiology and Psychosis in Parkinson's and Alzheimer's Disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
The Psychosis in Parkinson's and Alzheimer's Disease market report provides insights on the current and emerging therapies.
Psychosis in Parkinson's and Alzheimer's Disease market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Psychosis in Parkinson's and Alzheimer's Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Psychosis in Parkinson's and Alzheimer's Disease market.

Got queries? Click here to know more about the Psychosis in Parkinson's and Alzheimer's Disease Market Landscape.

Psychosis in Parkinson's and Alzheimer's Disease Overview

According to the National Institute of Mental Health (NIMH), psychosis is a set of symptoms that disrupt an individual's mind, leading to a loss of connection with reality. During a psychotic episode, a person's thoughts and perceptions become distorted, making it difficult to distinguish between what is real and what is not.

Psychosis is generally classified into three main categories: idiopathic psychosis, psychosis caused by medical conditions (such as neurodegenerative disorders), and toxic psychosis, which results from substance abuse, medications, or exposure to toxins. It is a syndrome found in multiple disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD), where severe psychotic symptoms can develop.

In Parkinson's disease psychosis (PDP), patients commonly experience visual hallucinations, along with other symptoms such as auditory hallucinations, delusions, illusions, depression, and anxiety. PDP is associated with higher morbidity and mortality rates, reduced health-promoting behaviors, and an increased likelihood of long-term care placement in nursing homes. Similarly, Alzheimer's disease psychosis (ADP) is frequently observed in individuals with AD, often presenting with dementia, auditory and visual hallucinations, and progressive cognitive decline. These symptoms worsen over time, significantly impacting both life expectancy and quality of life.

Psychosis in Parkinson's and Alzheimer's Disease Market Outlook

Psychosis is a common occurrence in individuals with Alzheimer's disease, persisting throughout the progression of the illness. Research suggests that more than half of Alzheimer's patients will experience psychotic symptoms at some point during their disease.

Antipsychotic medications remain the primary treatment for psychotic disorders and episodes, with the selection, dosage, and administration of drugs varying based on the specific condition. In addition to pharmacological treatment, caregivers and family members play a crucial role in managing psychosis by fostering a safe and supportive environment. Furthermore, cognitive behavioral therapy (CBT) is often recommended as an initial treatment approach for individuals with psychotic symptoms.

Although no standardized treatment guidelines exist, pimavanserin (34 mg/day) is the first-line pharmacotherapy for Parkinson's disease psychosis, as it is the only FDA-approved drug for the condition and has a low risk of severe adverse effects. If pimavanserin is unavailable or ineffective, clozapine (up to 50 mg/day) or quetiapine (gradually increased to 150 mg/day) may be considered. However, quetiapine may not adequately alleviate psychotic symptoms in some patients, while clozapine carries the risk of agranulocytosis, requiring frequent blood monitoring.

There is an urgent need for more effective targeted therapies for psychosis in both Alzheimer's and Parkinson's disease, as existing treatments are often limited by side effects such as hallucinations, confusion, and nausea. With no FDA-approved medication for Alzheimer's disease psychosis, developing precise risk profiles and optimizing the use of current antipsychotics remains a critical objective.

To address the unmet medical needs in this space, several late-stage drug candidates are being developed. These include KarXT (xanomeline-trospium) by Karuna Therapeutics, Ulotaront (SEP-363856) by Sunovion Pharmaceuticals, and FANAPT (iloperidone), which hold promise for advancing treatment options for psychosis associated with neurodegenerative diseases.

Psychosis in Parkinson's and Alzheimer's Disease Marketed Drugs
NUPLAZID (pimavanserin): Acadia Pharmaceuticals

Psychosis in Parkinson's and Alzheimer's Disease Emerging Drugs

Ulotaront (SEP-363856): Sunovion Pharmaceuticals
KarXT (xanomeline-trospium): Karuna Therapeutics
ITI-1284: Intra-Cellular Therapies

Scope of the Psychosis in Parkinson's and Alzheimer's Disease Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Psychosis in Parkinson's and Alzheimer's Disease Companies: Karuna Therapeutics, Sunovion Pharmaceuticals, Intra-Cellular Therapies, Acadia Pharmaceuticals, and others
Key Psychosis in Parkinson's and Alzheimer's Disease Therapies: NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others
Psychosis in Parkinson's and Alzheimer's Disease Therapeutic Assessment: Psychosis in Parkinson's and Alzheimer's Disease current marketed and Psychosis in Parkinson's and Alzheimer's Disease emerging therapies
Psychosis in Parkinson's and Alzheimer's Disease Market Dynamics: Psychosis in Parkinson's and Alzheimer's Disease market drivers and Psychosis in Parkinson's and Alzheimer's Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Psychosis in Parkinson's and Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Psychosis in Parkinson's and Alzheimer's Disease Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Psychosis in Parkinson's and Alzheimer's Disease Patient Share (%) Overview at a Glance
5. Psychosis in Parkinson's and Alzheimer's Disease Market Overview at a Glance
6. Psychosis in Parkinson's and Alzheimer's Disease Disease Background and Overview
7. Psychosis in Parkinson's and Alzheimer's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Psychosis in Parkinson's and Alzheimer's Disease
9. Psychosis in Parkinson's and Alzheimer's Disease Current Treatment and Medical Practices
10. Unmet Needs
11. Psychosis in Parkinson's and Alzheimer's Disease Emerging Therapies
12. Psychosis in Parkinson's and Alzheimer's Disease Market Outlook
13. Country-Wise Psychosis in Parkinson's and Alzheimer's Disease Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Psychosis in Parkinson's and Alzheimer's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Psychosis in Parkinson's and Alzheimer's Disease Market Outlook 2034.
Related Reports:

Psychosis in Parkinson's and Alzheimer's Disease Pipeline Insights, DelveInsight

"Psychosis in Parkinson's and Alzheimer's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Psychosis in Parkinson's and Alzheimer's Disease market. A detailed picture of the Psychosis in Parkinson's and Alzheimer's Disease pipeline landscape is provided, which includes the disease overview and Psychosis in Parkinson's and Alzheimer's Disease treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.